Regulation of complement inhibitors (CD55, CD35, CD59, and CD46) is important in autoantibody-mediated complement activation and is impaired in autoimmune diseases such as SLE, rheumatoid arthritis, and bullous pemphigoid [15]. This evidence concerns the gene CR1 and rheumatoid arthritis.